Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Inclusion Criteria: * Histologically confirmed renal cell carcinoma in either primary or metastatic lesions. Non-clear histology will be allowed. * Disease progression on a VEGF-targeted tyrosine kinase inhibitor as the most recent therapy or have experienced intolerable toxicity so as require discontinuation. Only one prior VEGF-targeted tyrosine kinase inhibitor. * Must be off of VEGF-targeted tyrosine kinase inhibitor for 2 weeks or greater. * One measurable lesion which is not curable by standard radiation therapy or surgery. * The enrolling site must agree to obtain paraffin-embedded tumor blocks or at least 10 unstained, paraffin-embedded slides for submission for correlative studies. * 18 years of age or older * ECOG Performance Status of 0 or 1 * Baseline laboratory values as outlined in the protocol * Life expectancy of greater than 3 months * No prior malignancy diagnosed within the past three years, other than superficial basal cell and superficial squamous cell, or carcinoma in situ of the cervix. Exclusion Criteria: * Known CNS disease, except for treated brain metastases * Previously treated with avastin or mTOR inhibitors * Other then VEFG-targeted TKI, patients may only have had prior immunotherapy or chemotherapy for stage IV disease * History of allergic reaction to Chinese hamster ovary cell products, other recombinant antibodies, or compounds of similar chemical or biologic composition to avastin or temsirolimus * History of bleeding diathesis or coagulopathy. Therapeutic anticoagulants are allowed * Patients with clinically significant cardiovascular disease * Patients receiving enzyme-inducing antiepileptic drugs or any other CYP3A4 inducer such as rifampin or St. John's wort * No serious non-healing wound, ulcer or bone fracture * No uncontrolled intercurrent illness including , but not limited to, ongoing active infection requiring parental antibiotics or psychiatric illness/social situations that would limit compliance with study requirements * HIV-positive receiving combination anti-retroviral therapy * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of vascular access device, within 7 days prior to enrollment on study * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Known hypersensitivity to any component of avastin or temsirolimus * Life expectancy of less than 12 weeks * History of hemoptysis within 1 month prior to day 1